Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 4
1993 9
1994 8
1995 7
1996 16
1997 23
1998 40
1999 86
2000 102
2001 117
2002 107
2003 112
2004 107
2005 122
2006 125
2007 96
2008 85
2009 86
2010 86
2011 70
2012 70
2013 58
2014 51
2015 49
2016 72
2017 59
2018 46
2019 61
2020 59
2021 46
2022 32
2023 29
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

1,888 results

Results by year

Filters applied: . Clear all
Page 1
Hyperhomocysteinemia in Cardiovascular Diseases: Revisiting Observational Studies and Clinical Trials.
Guéant JL, Guéant-Rodriguez RM, Oussalah A, Zuily S, Rosenberg I. Guéant JL, et al. Thromb Haemost. 2023 Mar;123(3):270-282. doi: 10.1055/a-1952-1946. Epub 2022 Sep 28. Thromb Haemost. 2023. PMID: 36170884 Free article. Review.
In contrast, moderate hyperhomocysteinemia (15-30 mol/L) is a modest predictor of cardiovascular risk. The recognition of homocysteine as a cardiovascular risk factor has been challenged by some but not all randomized clinical trials. We reviewed the main dat …
In contrast, moderate hyperhomocysteinemia (15-30 mol/L) is a modest predictor of cardiovascular risk. The recognition of homocystein …
Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials.
Yu JT, Xu W, Tan CC, Andrieu S, Suckling J, Evangelou E, Pan A, Zhang C, Jia J, Feng L, Kua EH, Wang YJ, Wang HF, Tan MS, Li JQ, Hou XH, Wan Y, Tan L, Mok V, Tan L, Dong Q, Touchon J, Gauthier S, Aisen PS, Vellas B. Yu JT, et al. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1201-1209. doi: 10.1136/jnnp-2019-321913. Epub 2020 Jul 20. J Neurol Neurosurg Psychiatry. 2020. PMID: 32690803 Free PMC article.
METHODS: Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-e …
METHODS: Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OP …
Mecobalamin.
Zhang YF, Ning G. Zhang YF, et al. Expert Opin Investig Drugs. 2008 Jun;17(6):953-64. doi: 10.1517/13543784.17.6.953. Expert Opin Investig Drugs. 2008. PMID: 18491996 Review.
Since the discovery of mecobalamin, it has been applied mainly in the treatment of hyperhomocysteinaemia and peripheral neuropathy. However, there is still lack of a systemic review on the clinical administration of mecobalamin and its potential mechanism. OBJECTIVE: To re …
Since the discovery of mecobalamin, it has been applied mainly in the treatment of hyperhomocysteinaemia and peripheral neuropathy. However, …
The treatment of hyperhomocysteinemia.
Maron BA, Loscalzo J. Maron BA, et al. Annu Rev Med. 2009;60:39-54. doi: 10.1146/annurev.med.60.041807.123308. Annu Rev Med. 2009. PMID: 18729731 Free PMC article. Review.
Although combined folic acid and B-vitamin therapy substantially reduces homocysteine levels, results from randomized placebo-controlled clinical trials testing the effect of vitamin therapy on outcome in these diseases have generally fallen short of expectations. . …
Although combined folic acid and B-vitamin therapy substantially reduces homocysteine levels, results from randomized placebo-control …
Hyperhomocysteinemia and venous thrombosis.
Bos GM, den Heijer M. Bos GM, et al. Semin Thromb Hemost. 1998;24(4):387-91. doi: 10.1055/s-2007-996027. Semin Thromb Hemost. 1998. PMID: 9763356 Review.
More recently, the subject of hyperhomocysteinemia and venous thrombosis has received much attention. In this article, we discuss the issue of hyperhomocysteinemia, in general, the known causes of hyperhomocysteinemia and the association with venous thrombosi …
More recently, the subject of hyperhomocysteinemia and venous thrombosis has received much attention. In this article, we discuss the …
Homocyst(e)ine and stroke.
Furie KL, Kelly PJ. Furie KL, et al. Semin Neurol. 2006 Feb;26(1):24-32. doi: 10.1055/s-2006-933306. Semin Neurol. 2006. PMID: 16479441 Review.
Although most commonly associated with large-artery atherosclerosis and venous thrombosis, hyperhomocysteinemia may contribute to stroke by other mechanisms as well. ...The Vitamin Intervention in Stroke Prevention study failed to prove that high-dose supplementation with …
Although most commonly associated with large-artery atherosclerosis and venous thrombosis, hyperhomocysteinemia may contribute to str …
Hyperhomocysteinemia, atherosclerosis and thrombosis.
Cattaneo M. Cattaneo M. Thromb Haemost. 1999 Feb;81(2):165-76. Thromb Haemost. 1999. PMID: 10063987 Review.
In the last two decades, a growing amount of interest has focused on mild-to-moderate hyperhomocysteinemia as a risk factor of thromboembolic diseases. Case-control and cross-sectional studies clearly indicated that mild-to-moderate hyperhomocysteinemia is associate …
In the last two decades, a growing amount of interest has focused on mild-to-moderate hyperhomocysteinemia as a risk factor of thromb …
Homocysteine, hyperhomocysteinemia and vascular contributions to cognitive impairment and dementia (VCID).
Hainsworth AH, Yeo NE, Weekman EM, Wilcock DM. Hainsworth AH, et al. Biochim Biophys Acta. 2016 May;1862(5):1008-17. doi: 10.1016/j.bbadis.2015.11.015. Epub 2015 Dec 9. Biochim Biophys Acta. 2016. PMID: 26689889 Free PMC article. Review.
While rare genetic mutations (CBS, MTHFR) cause severe hyperhomocysteinemia ([HCy]: 100-200muM), mild-moderate hyperhomocysteinemia ([HCy]: 10-100muM) is common in older people, and is an independent risk factor for stroke and cognitive impairment. ...Effects of HCy …
While rare genetic mutations (CBS, MTHFR) cause severe hyperhomocysteinemia ([HCy]: 100-200muM), mild-moderate hyperhomocysteinemi …
Hyperhomocysteinemia and thrombosis.
Cattaneo M. Cattaneo M. Lipids. 2001;36 Suppl:S13-26. doi: 10.1007/s11745-001-0677-9. Lipids. 2001. PMID: 11837987 Review.
In 1969, McCully first reported the presence of severe atherosclerotic lesions in patients with severe hyperhomocysteinemia and hypothesized the existence of a pathogenic link between hyperhomocysteinemia and atherogenesis. ...The mainstay of treatment of hyperho …
In 1969, McCully first reported the presence of severe atherosclerotic lesions in patients with severe hyperhomocysteinemia and hypot …
Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial.
Bao H, Huang X, Li P, Sheng C, Zhang J, Wang Z, Song D, Hu L, Ding C, Cheng Z, Yao C, Chen G, Cui Y, Qin X, Tang G, Wang X, Huo Y, Cheng X, Wang J. Bao H, et al. J Clin Hypertens (Greenwich). 2023 Aug;25(8):689-699. doi: 10.1111/jch.14697. Epub 2023 Jul 11. J Clin Hypertens (Greenwich). 2023. PMID: 37433173 Free PMC article. Clinical Trial.
Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke. ...However, intolerance to ACEI is common in Asians and amlodipine can be alternative. This is a multicenter, randomized, double-blind, parallel-controlled clinical tri …
Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke. ...However, intolerance to ACEI is common in …
1,888 results